Brain Cancer News and Research RSS Feed - Brain Cancer News and Research

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.
Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells. [More]

TGen honors two philanthropists for supporting TGen's research on brain, colon and prostate cancer

The Translational Genomics Research Institute (TGen) recently honored two significant Arizona philanthropists at their annual Founders Dinner for their support of TGen's research into brain, colon and prostate cancer. The event took place March 28 in Scottsdale. [More]
Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9. [More]
Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Skatchewan is a vast prairie province in the middle of Canada. It's home to hockey great Gordie Howe and the world's first curling museum. But Canadians know it for another reason: it's the birthplace of the country's single-payer health-care system. [More]
Multiple genomic data could help improve studies of association between genes and disease

Multiple genomic data could help improve studies of association between genes and disease

The difference between merely throwing around buzzwords like "personalized medicine" and "big data" and delivering on their medical promise is in the details of developing methods for analyzing and interpreting genomic data. In a pair of new papers, Brown University epidemiologist Yen-Tsung Huang and colleagues show how integrating different kinds of genomic data could improve studies of the association between genes and disease. [More]
Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Researchers at the University of Alabama at Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer. [More]

Researchers find new molecular targets for aggressive brain tumor

Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Tuesday, April 8, 2014 at the American Association of Cancer Researchers conference in San Diego, CA. The research identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known as glioblastoma multiforme. [More]
DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. [More]
Researchers identify potential treatment targets for incurable form of pediatric brain cancer

Researchers identify potential treatment targets for incurable form of pediatric brain cancer

Researchers from the University of Toronto's Department of Laboratory Medicine and Pathobiology (LMP) have defined potential treatment targets for a previously incurable form of pediatric brain cancer called Diffuse Intrinsic Pontine Glioma (DIPG). [More]
Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors. [More]

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases. [More]

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders: [More]
Market research report on personalized cancer drugs

Market research report on personalized cancer drugs

Research and Markets has announced the addition of the "Concise Analysis of International Personalizing Cancer Drugs Trends" report to their offering. [More]
e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

e-Therapeutics plc announces today that it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial being conducted at three centres in the UK. [More]
UMass Medical School students win 2014 Harold M. Weintraub Graduate Student Award

UMass Medical School students win 2014 Harold M. Weintraub Graduate Student Award

Colin Conine and Emma Watson, PhD students in the Graduate School of Biomedical Sciences (GSBS) at the University of Massachusetts Medical School, received the 2014 Harold M. Weintraub Graduate Student Award for research into the mechanisms governing epigenetic inheritance and the complex interactions between diet, gene expression and physiology. [More]

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA. [More]

GenSpera enrolls first patient in Phase II trial of compound G-202 in patients with glioblastoma multiforme

GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. [More]
Thirteen graduate students to receive 2014 Harold M. Weintraub Graduate Student Award

Thirteen graduate students to receive 2014 Harold M. Weintraub Graduate Student Award

Thirteen graduate students from institutes throughout North America have been chosen to receive the 2014 Harold M. Weintraub Graduate Student Award sponsored by the Basic Sciences Division of Fred Hutchinson Cancer Research Center. [More]
Skin cancer may increase risk of other cancers later in life

Skin cancer may increase risk of other cancers later in life

Australian author on the paper, Professor Rodney Sinclair, Professor of Medicine at the University of Melbourne and Director of Dermatology at Epworth HealthCare said that the risk decreased significantly with increasing age, but it remains higher compared with individuals who have never had NMSC. [More]
FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget. [More]